Navigation Links
Biomarkers predict risk for invasive breast cancer years before the tumor develops
Date:11/12/2007

A team of scientists from the University of California San Francisco has identified distinct molecular markers that predict whether or not a woman is likely to develop subsequent invasive cancer after initial diagnosis with a noninvasive form of early breast cancer. The research, published by Cell Press in the November issue of Cancer Cell, provides critical information that can be used to determine whether a woman should receive more or less aggressive therapy.

Approximately 12-15% of women diagnosed with ductal carcinoma in situ (DCIS), a tumor limited to milk ducts, develop a subsequent invasive cancer event within the first decade after surgical lumpectomy. However, due to the absence of reliable predictors to identify those women that will develop future tumors formation, all women diagnosed with DCIS tend to be offered similar treatment options. Identification of biomarkers that predict future tumor development would allow us to stratify a womens individual risk for subsequent invasive tumors and avoid over- and under- treatment, says lead author Dr. Thea D. Tlsty and clinician, Dr. Karla Kerlokowske, both from the Comprehensive Cancer Center at the University of California San Francisco.

Dr. Tlsty, Gauthier and Berman hypothesized that cells capable of activating pathways linked to stress-induced cell death would not form subsequent tumors while cells that bypass stress signals would be more likely to eventually progress to tumor formation. The researchers evaluated molecular characteristics and their association with outcome in a group of women diagnosed with DCIS and found that expression of biomarkers indicative of a short-circuited response to cellular stress predicts DCIS with a worse outcome and is a defining characteristic of an aggressive phenotype called basal-like tumors. Conversely, a disease-free prognosis is associated with an intact response to cellular stress.

Mechanistic studies indicated that deregulation of the tumor suppressor Rb pathway is linked with the highly proliferative basal-like subtype of breast cancer and cancer recurrence. The combination of stress-activation and deregulation of p16/Rb signaling may represent a defining signature of basal-like carcinogenesis that can be assayed far in advance to the development of invasive disease and present clinical opportunities for appropriate aggressive intervention, concludes Dr. Tlsty.


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Penn School of Medicine receives $2.3 million to study biomarkers of cigarette smoke exposure
2. Study makes progress in zoning in on biomarkers for better colon cancer treatment
3. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
4. UCLA researchers identify markers that may predict diabetes in still-healthy people
5. Use of certain lipid measures not more effective in predicting coronary heart disease
6. First biomarker discovered that predicts prostate cancer outcome
7. Brain Lesions Predict MS Progression
8. ZIP codes and property values predict obesity rates
9. Work Time Predicts Sleep Time
10. Thomson Scientific Predicts Nobel Laureates
11. Segal Survey Predicts Declines in Trends for Fifth Consecutive Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... 16, 2017 , ... San Francisco dentist, Dr. Ben Amini , the ... device which is capable of taking digital impressions of teeth and gums. Conventional bite ... CAD CAM restorations , in terms of speed, efficiency and patient comfort. Increasingly, digital ...
(Date:1/15/2017)... ... January 15, 2017 , ... In this role, Courtney will ... States for the asthma & allergy friendly mark. This certification program was created by ... identify consumer products to be more suitable for the 60+ million people living in ...
(Date:1/15/2017)... ... January 15, 2017 , ... Accreditation Commission for Health ... its specialty care services. Albertsons Companies is the largest national food and ... pharmacy patients. , Accreditation by ACHC reflects Albertsons Companies’ dedication and commitment to ...
(Date:1/15/2017)... ... 2017 , ... Wondering where to go this Valentine's Day? Well, there is ... a romantic, lobster feast in the comfort of your own home. Lobster Gram is ... will be featured until February 15th, 2017. , Romantic Dinner one is Lobster ...
(Date:1/14/2017)... , ... January 14, 2017 , ... ... distinctions among their expanding line of activated charcoal products. With more and more ... of categorizing their products according to how they cater to specific needs. , ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... This morning, Stock-Callers.com draws attention ... fared at yesterday,s closing bell: Clovis Oncology Inc. (NASDAQ: ... GALE ), and ACADIA Pharmaceuticals Inc. (NASDAQ: ... processes to develop technologies and products that combat debilitating ... hungry, use less and cleaner energy, and provide safer, ...
(Date:1/13/2017)...  Secretary of Health Karen Murphy today ... at Misericordia University and discussed the Wolf Administration,s efforts ... . "The opioid epidemic is the ... my professional career," Secretary Murphy said. "This area of ... by heroin and prescription opioid overdoses. Across the commonwealth ...
(Date:1/13/2017)... Research and Markets has announced the addition of the ... offering. ... fibrosis (CF) is a progressive genetic condition and is the result ... (CFTR) gene from both parents. The defective CFTR genes produce faulty ... buildup of a thick and sticky mucus in the lungs and ...
Breaking Medicine Technology: